Company intelligence / Profile preview

Khondrion

Nijmegen, Gelderland, Netherlandskhondrion.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Sonlicromanol has shown promise as a first-in-class brain‐penetrant redox-modulator with anti-inflammatory properties. It has been tested in three clinical trials for patients with m.3243A>G PMD and completed the first wave of a six-month Phase II study in children. The drug has received orphan drug designations for several rare mitochondrial diseases and rare pediatric disease designation from the FDA. A pivotal Phase III trial was cleared by the FDA to proceed as of November 2024.

Therapeutic areas: EndocrinologyRare DiseasesNeurology
Modalities: Small molecules (notably redox-modulators)
Industry: Biotech

Drug pipeline

3 assets

sonlicromanol

2 more assets in the full pipeline.

Request access →

Partnerships

Extensive academic collaborations mentioned but no specific major pharma partnerships named publicly

Beyond the preview

Go deeper on Khondrion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Khondrion.

Explore the full profile